{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:36:46Z","timestamp":1791333406204,"version":"4.3.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K23 CA201594"],"award-info":[{"award-number":["K23 CA201594"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA076292"],"award-info":[{"award-number":["P30 CA076292"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009164","name":"Moffitt Cancer Center","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100009164","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jtct.2022.03.023","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:37:44Z","timestamp":1648780664000},"page":"305.e1-305.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-8132","authenticated-orcid":false,"given":"Aasha I.","family":"Hoogland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Logue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuhya","family":"Kommalapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly A.","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1742-3280","authenticated-orcid":false,"given":"Ashley M.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Eisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-4689","authenticated-orcid":false,"given":"Brent J.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-7020","authenticated-orcid":false,"given":"Shannon M.","family":"Christy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey W.","family":"Bulls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Booth-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5291-5945","authenticated-orcid":false,"given":"Reena V.","family":"Jayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepideh","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Chavez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Lazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-3711","authenticated-orcid":false,"given":"Heather S.L.","family":"Jim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.03.023_bib0001","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.023_bib0002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.03.023_bib0003","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2022.03.023_bib0004","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety and long-term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.023_bib0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.03.023_bib0006","series-title":"Proceedings from the ASH 2018 - 60th American Society of Hematology Annual Meeting and Exposition. December 1-4","article-title":"Aggressive lymphoma (diffuse large B-cell and other aggressive B-cell non-Hodgkin lymphomas)\u2014results from retrospective\/observational studies: outcomes with CD19 CAR T therapy and checkpoint blockade in the real-world setting","author":"Jacobson","year":"2018"},{"key":"10.1016\/j.jtct.2022.03.023_bib0007","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jcyt.2020.01.015","article-title":"The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma","volume":"22","author":"Cao","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2022.03.023_bib0008","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.023_bib0009","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.023_bib0010","first-page":"50","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","author":"Gauthier","year":"2018","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.jtct.2022.03.023_bib0011","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jtct.2022.03.023_bib0012","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.03.023_bib0013","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.03.023_bib0014","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/bmt.2013.61","article-title":"A systematic review and meta-analysis of changes in cognitive functioning in adults undergoing hematopoietic cell transplantation","volume":"48","author":"Phillips","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.023_bib0015","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1200\/JCO.2011.39.5640","article-title":"Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy","volume":"30","author":"Jim","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.023_bib0016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/brbi.1995.1012","article-title":"Spatial learning impairment in mice infected with Legionella pneumophila or administered exogenous interleukin-1-beta","volume":"9","author":"Gibertini","year":"1995","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jtct.2022.03.023_bib0017","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.bbi.2009.03.001","article-title":"Memory impairment induced by IL-1beta is reversed by alpha-MSH through central melanocortin-4 receptors","volume":"23","author":"Gonzalez","year":"2009","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jtct.2022.03.023_bib0018","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.neuropharm.2004.02.012","article-title":"Involvement of arachidonic acid cascade in working memory impairment induced by interleukin-1 beta","volume":"46","author":"Matsumoto","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jtct.2022.03.023_bib0019","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.2006.07.9079","article-title":"Impact of delirium on cognition, distress, and health-related quality of life after hematopoietic stem-cell transplantation","volume":"25","author":"Fann","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.023_bib0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1200\/JCO.2010.28.4521","article-title":"Pre- and post-transplantation risk factors for delirium onset and severity in patients undergoing hematopoietic stem-cell transplantation","volume":"29","author":"Fann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.023_bib0021","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.023_bib0022","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2004-03-1155","article-title":"Neuropsychologic changes from before transplantation to 1 year in patients receiving myeloablative allogeneic hematopoietic cell transplant","volume":"104","author":"Syrjala","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.023_bib0023","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/cam4.3664","article-title":"Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel","volume":"10","author":"Hoogland","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtct.2022.03.023_bib0024","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.bmt.1705108","article-title":"Characteristics and correlates of cognitive functioning following bone marrow transplantation","volume":"36","author":"Booth-Jones","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.023_bib0025","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/cncr.22962","article-title":"Changes in cognitive functioning in the year after hematopoietic stem cell transplantation","volume":"110","author":"Jacobs","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.03.023_bib0026","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1470-2045(10)70294-1","article-title":"International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer","volume":"12","author":"Wefel","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.03.023_bib0027","series-title":"Wechsler Test of Adult Reading","author":"Wechsler","year":"2001"},{"key":"10.1016\/j.jtct.2022.03.023_bib0028","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1076\/jcen.20.3.310.823","article-title":"The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity","volume":"20","author":"Randolph","year":"1998","journal-title":"J Clin Exp Neuropsychol"},{"key":"10.1016\/j.jtct.2022.03.023_bib0029","series-title":"Connors\u2019 Continuous Performance Test (CPT)","author":"Connors","year":"1994"},{"key":"10.1016\/j.jtct.2022.03.023_bib0030","author":"Golden","year":"1978","journal-title":"Stroop Color and Word Test: a Manual for Clinical and Experimental Uses"},{"key":"10.1016\/j.jtct.2022.03.023_bib0031","series-title":"A Compedium of Neuropsychological Tests: Administration, Norms and Commentary","author":"Spreen","year":"1998"},{"key":"10.1016\/j.jtct.2022.03.023_bib0032","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1998"},{"key":"10.1016\/j.jtct.2022.03.023_bib0033","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1002\/cncr.28323","article-title":"Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant","volume":"119","author":"Jones","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.03.023_bib0034","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1002\/cncr.26645","article-title":"Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation","volume":"118","author":"Jim","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.03.023_bib0035","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2022.03.023_bib0036","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2022.03.023_bib0037","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41409-017-0055-7","article-title":"Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT","volume":"53","author":"Buchbinder","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.023_bib0038","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/arclin\/acs141","article-title":"Predictors of neuropsychological change in patients with chronic myelogenous leukemia and myelodysplastic syndrome","volume":"28","author":"Meadows","year":"2013","journal-title":"Arch Clin Neuropsychol"},{"key":"10.1016\/j.jtct.2022.03.023_bib0039","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.03.023_bib0040","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cncr.24192","article-title":"Cognitive functioning in breast cancer survivors: a controlled comparison","volume":"115","author":"Jim","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.03.023_bib0041","first-page":"21","article-title":"Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison","volume":"18","author":"Jim","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jtct.2022.03.023_bib0042","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/pon.3159","article-title":"Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study","volume":"22","author":"Scherwath","year":"2013","journal-title":"Psychooncology"},{"key":"10.1016\/j.jtct.2022.03.023_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101287","article-title":"Toxicities associated with adoptive cellular therapies","volume":"34","author":"Hansen","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtct.2022.03.023_bib0044","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.bbmt.2017.08.006","article-title":"The role of age in neurocognitive functioning among adult allogeneic hematopoietic cell transplant recipients","volume":"23","author":"Hoogland","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.023_bib0045","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1001\/jama.291.19.2335","article-title":"Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma","volume":"291","author":"Syrjala","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jtct.2022.03.023_bib0046","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.bbmt.2016.08.012","article-title":"Trajectories of quality of life after hematopoietic cell transplantation: secondary analysis of Blood and Marrow Transplant Clinical Trials Network 0902 data","volume":"22","author":"Jim","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.023_bib0047","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.03.023_bib0048","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.023_bib0049","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2022.03.023_bib0050","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/cncr.29891","article-title":"A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction","volume":"122","author":"Ferguson","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.03.023_bib0051","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines for Patients 2020: Survivorship care for cancer-related late and long-term effects. Available at: https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/survivorship-crl-patient.pdf. Accessed March 10, 2022."},{"key":"10.1016\/j.jtct.2022.03.023_bib0052","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejon.2012.06.002","article-title":"Impact of perceived cognitive impairment in breast cancer survivors","volume":"17","author":"Von Ah","year":"2013","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.jtct.2022.03.023_bib0053","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/bmt.2016.2","article-title":"Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation","volume":"51","author":"Mayo","year":"2016","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722011885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722011885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:04:04Z","timestamp":1763003044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722011885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666636722011885"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.03.023","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}